|
Hypersensitive syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The goal of this research was to investigate the linkage disequilibrium between rs9263726 and HLA-B*58:01 in different Chinese ethnic groups (Han, Tibet, and Hui) and to study the feasibility of rs9263726 replacing HLA-B*58:01 as an efficient indicator of potential allopurinol hypersensitivity syndrome.
|
30080910 |
2019 |
|
Hypersensitive syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association with HLA-A*31:01 in patients with SCAR was mainly driven by hypersensitivity syndrome (OR = 12.9; P = 2.1 × 10<sup>-9</sup> ) rather than by Stevens-Johnson syndrome/toxic epidermal necrolysis cases, which showed an association with HLA-B*57:01.
|
31066027 |
2019 |
|
Hypersensitive syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
|
30916737 |
2019 |
|
Hypersensitive syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Joint association of carrying HLA-B*13:01 gene and human herpesvirus-6 with occupational trichloroethylene hypersensitivity syndrome.
|
30758654 |
2019 |
|
Hypersensitive syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
HLA-B*13:01 has been identified as a strong risk factor of dapsone hypersensitivity syndrome; however, its low positive predictive value indicated that additional genetic variants may be involved in the disease development.
|
29233746 |
2018 |
|
Hypersensitive syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.
|
28857441 |
2017 |
|
Hypersensitive syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Most notable examples include human leukocyte antigen (HLA)-B*57:01 allele and abacavir hypersensitivity syndrome or HLA-B*15:02 and HLA-B*58:01 alleles related to severe cutaneous reactions induced by carbamazepine and allopurinol, respectively.
|
28162244 |
2017 |
|
Hypersensitive syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association between abacavir hypersensitivity syndrome and HLA-B*57:01 is one exception that has been resolved at a molecular and mechanistic level.
|
28695285 |
2017 |
|
Hypersensitive syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome.
|
28870516 |
2017 |
|
Hypersensitive syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacogenetic screening for HLA-B*57:01 prior to abacavir therapy has significantly reduced the incidence of abacavir hypersensitivity syndrome in clinical practice.
|
24777842 |
2015 |
|
Hypersensitive syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Hypersensitivity reaction to abacavir (ABC hypersensitivity syndrome, AHS) is strongly associated with the presence of the HLA-B*57:01 allele.
|
25922880 |
2015 |
|
Hypersensitive syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients carrying HLA-B*15:02 are at strongly increased risk for CBZ-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) in populations where HLA-B*15:02 is common, but not CBZ-induced hypersensitivity syndrome (HSS) or maculopapular exanthema (MPE).
|
24597466 |
2014 |
|
Hypersensitive syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We recruited 32 cases, 5 with Steven Johnson Syndrome/Toxic Epidermolytic Necrolysis (SJS/TEN) (2 Chinese, 3 Malay), 6 with hypersensitivity syndrome (HSS) (5 Chinese, 1 Indian), 11 with minor drug reactions (9 Chinese, 2 Malay) and 10 controls (7 Chinese, 2 Malay, 1 Indian).HLA-B*1502 allelism was assayed.
|
24225276 |
2014 |
|
Hypersensitive syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presence of HLA-B*13:01 had a sensitivity of 85.5% and a specificity of 85.7% as a predictor of the dapsone hypersensitivity syndrome, and its absence was associated with a reduction in risk by a factor of 7 (from 1.4% to 0.2%).
|
24152261 |
2013 |
|
Hypersensitive syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
HLA-B*57:01 is strongly associated with abacavir-induced hypersensitivity syndrome.
|
23635947 |
2013 |
|
Hypersensitive syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The associations between HLA-B*57:01 and abacavir hypersensitivity syndrome, and HLA-B*15:02 and carbamazepine-induced bullous skin disease have provided new insights into the mechanism associated with hypersensitivity reactions to these drugs.
|
23141566 |
2013 |
|
Hypersensitive syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
HLA-B*5701 screening to prevent abacavir hypersensitivity syndrome is an example of a test now in widespread routine clinical use in the developed world.
|
20602616 |
2010 |
|
Hypersensitive syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Special emphasis is devoted to the studies that have resulted in clinical applications such as that of the pre-screening of HLA B*5701 for avoiding abacavir-related hypersensitivity syndrome.
|
20216907 |
2010 |
|
Hypersensitive syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two important examples are discussed, the association of APOE genotypes to the demonstration of actionable efficacy signals for the use of rosiglitazone for Alzheimer's disease; and the identification of HLA-B(*)5701 as a highly sensitive and specific predictive marker for abacavir treated patients who will develop hypersensitivity syndrome (HSS).
|
18923406 |
2009 |